1. Home
  2. SDSTW vs ERNA Comparison

SDSTW vs ERNA Comparison

Compare SDSTW & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stardust Power Inc. Warrant

SDSTW

Stardust Power Inc. Warrant

N/A

Current Price

$0.15

Market Cap

6.8M

Sector

N/A

ML Signal

N/A

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

HOLD

Current Price

$3.35

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDSTW
ERNA
Founded
N/A
2018
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8M
7.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SDSTW
ERNA
Price
$0.15
$3.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.9K
548.8K
Earning Date
03-26-2025
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
N/A
N/A
Revenue
N/A
$582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.13
52 Week High
$0.30
$15.88

Technical Indicators

Market Signals
Indicator
SDSTW
ERNA
Relative Strength Index (RSI) 39.08 30.25
Support Level N/A $0.23
Resistance Level $0.12 $7.94
Average True Range (ATR) 0.01 0.74
MACD -0.00 -0.18
Stochastic Oscillator 1.73 1.21

Price Performance

Historical Comparison
SDSTW
ERNA

About SDSTW Stardust Power Inc. Warrant

Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: